Oncotelic Therapeutics (OTCQB: OTLC) launched an artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, targeting pharmaceutical, biotechnology, and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
The platform supports electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring, according to the company. Oncotelic also highlighted progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focusing on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic owns 45% of GMP Bio, a joint venture advancing additional drug candidates. The company also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and joint development work with TechForce Robotics, Oncotelic's strategic robotics and automation partner.
TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications.
For more information, visit www.oncotelic.com and www.techforcerobotics.com.
